Contact the publisher of this press release

Clinical Innovations, Inc. Will be Participating in the Phase 3 Study DEFEND - DEFEND Testing Otelixizumab in New-Onset, Type 1 Diabetes Mellitus

Your message has been sent.
There were problems with your form submission